San Francisco, CA, United States
San Francisco, CA, United States

Time filter

Source Type

Patent
Cytokinetics Inc. | Date: 2015-04-28

Provided herein are compositions and methods for reducing the decline in vital capacity in a subject by administering to the subject a skeletal muscle troponin activator. Also provided are compositions and methods for reducing respiratory decline in a subject, as measured by slow vital capacity (SVC), by administering to the subject a skeletal muscle troponin activator.


Provided are compounds of Formula I:^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), R^(8), R^(9), X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Provided are compounds of Formula I:^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), R^(8), R^(9), X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Patent
Cytokinetics Inc. | Date: 2015-04-22

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.


Patent
Cytokinetics Inc. and Global Blood Therapeutics | Date: 2014-03-14

Provided are cycloalkyl- and cycloalkenyl-substituted benzaldehydes and heteroaldehydes of formula (I) that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions containing the modulators, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from increased tissue oxygenation.


Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R^(2), R^(4), R^(5), R^(6), R^(7), R^(8), R^(9), X, Z^(1), Z^(2), Z^(3), Z^(4 )and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia, wasting syndrome, frailty, cachexia, muscle spasm, post-surgical and post-traumatic muscle weakness, neuromuscular disease, and other indications.


Patent
Cytokinetics Inc. | Date: 2014-09-18

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.


Patent
Cytokinetics Inc. | Date: 2016-03-04

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), R^(7), X, Z^(1), Z^(2), Z^(3), Z^(4 )and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising sing a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.


Patent
Cytokinetics Inc. | Date: 2015-08-27

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Loading Cytokinetics Inc. collaborators
Loading Cytokinetics Inc. collaborators